<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00403988</url>
  </required_header>
  <id_info>
    <org_study_id>L_9116</org_study_id>
    <nct_id>NCT00403988</nct_id>
  </id_info>
  <brief_title>Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma</brief_title>
  <official_title>A Clinical Phase II Study of Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American University of Beirut Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>American University of Beirut Medical Center</source>
  <brief_summary>
    <textblock>
      Study Objective :&#xD;
&#xD;
      To assess the efficacy and the safety of the combination of Oxaliplatin, and Vinorelbine with&#xD;
      or without Trastuzumab as a salvage regimen in patients with Metastatic Breast Cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The results of a same study design have shown low response with important side effects.&#xD;
    Accordingly &amp; ethicly, the study has been stopped.&#xD;
  </why_stopped>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>During the Study Conduct</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time to progression (TTP).</measure>
    <time_frame>during the study conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tolerance</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity.</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic, histologically or cytologically proven breast cancer.&#xD;
&#xD;
          -  At least one bi-dimensionally measurable lesion.&#xD;
&#xD;
          -  Previous treatment with chemotherapy as first line for metastatic disease is mandatory&#xD;
             especially with anthracyclines +/- the Taxanes.&#xD;
&#xD;
          -  Treatment as adjuvant is allowed.&#xD;
&#xD;
          -  World Health Organization-ECOG performance status 0-2.&#xD;
&#xD;
          -  Adequate renal function (Creatinine &lt;= 1.4 or Creatinine clearance &gt;= 30 ml/min)&#xD;
&#xD;
          -  Adequate hepatic function (Liver Function Tests not more than 3 times the normal&#xD;
             values)&#xD;
&#xD;
          -  Adequate bone marrow reserve is required (Neutrophils (PMN) &gt;= 2000/mm2 and Platelets&#xD;
             &gt;= 100,000/mm2)&#xD;
&#xD;
          -  Patient who will receive Herceptin should have an over-expression of HER2-neu.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic peripheral neuropathy (National Cancer Institute common toxicity criteria&#xD;
             grade more than one).&#xD;
&#xD;
          -  Pregnant or breast-feeding.&#xD;
&#xD;
          -  History of prior malignancies (with the exception of excised cervical&#xD;
             carcinoma-in-situ or non-melanoma cell skin carcinoma).&#xD;
&#xD;
          -  Receiving or had received, any treatment with experimental drugs.&#xD;
&#xD;
          -  Had known brain or leptomeningeal involvement.&#xD;
&#xD;
          -  Had a serious medical condition like congestive heart failure or an Ejection Fraction&#xD;
             ≥ 40 %.&#xD;
&#xD;
          -  The presence of bone as a sole site of metastasis.&#xD;
&#xD;
          -  Radiation therapy to all areas of measurable disease less than four weeks before&#xD;
             treatment.&#xD;
&#xD;
          -  Creatinine two times above the normal range&#xD;
&#xD;
          -  Hypercalcemia&#xD;
&#xD;
          -  Evaluable but not a measurable disease as a sole site of metastasis: pleural effusion&#xD;
             - Ascites - Pericardial effusion.&#xD;
&#xD;
          -  Concomitant steroid intake for &gt; 4 weeks&#xD;
&#xD;
          -  Bilirubin two times above the normal range&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AmericanUBMC</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>November 23, 2006</study_first_submitted>
  <study_first_submitted_qc>November 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2006</study_first_posted>
  <last_update_submitted>November 3, 2008</last_update_submitted>
  <last_update_submitted_qc>November 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

